MedTrace Logo

Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

NCT00504543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 311

Last updated 2016-11-18

No results posted yet for this study

Summary

This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.

Conditions

  • Kidney Transplantation

Interventions

DRUG

AEB071

oral, twice daily

DRUG

Certican

twice daily

DRUG

Neoral

twice daily

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Colombia
  • Czechia
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Singapore
  • Slovakia
  • Spain
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504543 on ClinicalTrials.gov